Savings Effect

Sun Pharma (SPARC) Announces Sale of Priority Review Voucher for US $195 million

BSE Sensex and Nifty 50, are likely to open on a weak note on April 30, as indicated by GIFT Nifty, which is trading in the red at around 24,163.50.

'Supply Shock': Rising input costs and rupee weakness threaten FY27 growth, says FinMin report

FIIs net sell equities worth Rs 2,468 crore, DIIs net buy Rs 2,262 crore on April 29

OIL HITS WARTIME HIGH ON REPORT US EYING IRAN MILITARY OPTIONS

BIOCON: U.S. FDA COMPLETES PRE-LICENSE INSPECTION AT BENGALURU BIOSIMILARS FACILITY; RECEIVES 5 PROCEDURAL OBSERVATIONS WITH NO DATA INTEGRITY OR REPEAT ISSUES

STRING METAVERSE: BOARD APPROVES 2:9 SELECTIVE BONUS ISSUE FOR PUBLIC SHAREHOLDERS; PROMOTERS VOLUNTARILY WAIVE PARTICIPATION

WELSPUN ENTERPRISES: CO SECURES RUPEES 7,300 CR PUNE–SHIRUR PROJECT, BOOSTS ORDER BOOK TO RUPEES 18,755 CR

Adani Total Gas: Guidance - Management expects FY2027 revenue growth to be similar to FY2026, with potential for higher growth in newer geographical areas.|| Co forecasts approximately INR 1,500 crores in EBITDA for FY2027.- Concall Update

Piramal Pharma: Guidance - Concall Update For FY27, the company anticipates early to mid-teen revenue growth, with EBITDA and PAT growing faster. This revenue growth guidance is in INR terms, excluding contributions from the previously destocked on-patent commercial product. Revenue is expected to be H2 weighted, reflecting CDMO order delivery schedules and Kenalog integration, with momentum building from Q2. FY27 CapEx is projected at INR120 million to INR135 million, primarily for the ongoing Lexington expansion, targeting completion by end of CY27. Net debt to EBITDA is expected to remain around 3.6x for FY27, with a long-term intent to reduce it to 1x.